Equities

ITonis Inc

ITNS:PKC

ITonis Inc

Actions
  • Price (USD)0.0005
  • Today's Change0.00 / 0.00%
  • Shares traded93.49k
  • 1 Year change+25.00%
  • Beta0.0740
Data delayed at least 15 minutes, as of Jun 28 2024 18:39 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Itonis Inc. is a holding company. The Company, through the Itonis Pharmaceuticals division, produces and markets over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company’s Emesyl nausea relief product focuses on the general public who suffers from nausea. Emesyl products are available for purchase at https://www.amazon.com and www.Emesyl.com. The Company's subsidiaries include Itonis Holdings, Inc. and Paramount Discoveries, Inc.

  • Revenue in USD (TTM)0.00
  • Net income in USD-1.17m
  • Incorporated2005
  • Employees--
  • Location
    ITonis Inc22600-C Lambert Street, Suite 902LAKE FOREST 92630United StatesUSA
  • Phone+1 (949) 200-8887
  • Websitehttp://itonisholdings.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Evofem Biosciences Inc16.01m47.49m651.63k37.000.0011--0.01370.0407-5.92-5.920.0826-1.360.9351.722.73432,756.80295.02-211.64----63.65--315.54-1,031.550.0757-2.91----8.20--164.08---10.59--
ITonis Inc0.00-1.17m761.70k-----------0.0012-0.00120.00-0.00040.00-------187.63---1,169.36-------------0.8999---------506.86------
Medicale Corp0.00-53.64k1.60m-----------0.0091-0.00910.00-0.01210.00-------33,525.00-----------------54.88--------14.61------
DH Enchantment Inc1.87k-110.05k1.66m3.00------889.10-0.0001-0.00010.00-0.00110.0971--46.75623.33-571.54------132.62---5,885.03--0.0021-8.29-----97.25--12.89------
CYANOTECH CORP22.49m-4.62m2.26m86.00--0.1623--0.1006-0.7265-0.72653.532.010.78891.5310.73261,546.50-16.19-2.32-21.07-2.9629.5935.88-20.52-2.330.3702-5.930.3299---35.56-7.44-259.70--1.22--
Global Technologies Ltd454.51k36.30k2.94m------59.386.460.000.000.000030.000080.1066--6.90--0.8516------19.87--7.99------0.3005---86.35--19.11------
60 Degrees Pharmaceuticals Inc378.20k-1.07m3.09m2.00------8.16-0.1563-0.15630.05640.61210.04740.88271.90126,066.70-9.87-------23.45---208.43--6.77--0.0217---50.40--35.51------
Data as of Jun 28 2024. Currency figures normalised to ITonis Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.